Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Temporarily Closed to Accrual
To determine whether olaparib plus tremelimumab has adequate safety in the study population
A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.